{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:31:00Z","timestamp":1773693060568,"version":"3.50.1"},"reference-count":86,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nephro.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T13:54:15Z","timestamp":1575640455000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Toxicit\u00e9s r\u00e9nales des th\u00e9rapies cibl\u00e9es en oncologie"],"prefix":"10.1684","volume":"16","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2019.06.003_bib0430","unstructured":"National Cancer Institute. Targeted therapy. [Disponible sur\u00a0: www.cancer.gov\/about-cancer\/treatment\/types\/targetedtherapies]"},{"issue":"1","key":"10.1016\/j.nephro.2019.06.003_bib0850","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri","year":"2016","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nephro.2019.06.003_bib0435","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.kint.2016.06.027","article-title":"Renal effects of novel anti-cancer targeted therapies: a review of the FDA adverse event reporting system","volume":"90","author":"Jhaveri","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.06.003_bib0440","first-page":"F267","article-title":"Remnant kidney hypermetabolism and progression of chronic renal failure","volume":"254","author":"Harris","year":"1988","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0445","first-page":"F1117","article-title":"Response of rat inner medullary collecting duct to epidermal growth factor","volume":"256","author":"Harris","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0450","first-page":"F553","article-title":"Segmental distribution of epidermal growth factor binding sites in rabbit nephron","volume":"259","author":"Breyer","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0455","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/ndt\/gfw467","article-title":"Adverse kidney effects of epidermal growth factor receptor inhibitors","volume":"32","author":"Izzedine","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2019.06.003_bib0460","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1517\/14740338.2011.606213","article-title":"Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies","volume":"11","author":"Petrelli","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.nephro.2019.06.003_bib0465","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1007\/s13277-014-2983-9","article-title":"Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25\u00a0randomized clinical trials","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0470","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3816\/CCC.2006.n.033","article-title":"Cetuximab induced hypomagnesaemia in patients with colorectal cancer","volume":"6","author":"Fakih","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0475","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.critrevonc.2009.03.012","article-title":"Electrolyte disorders related to EGFR-targeting drugs","volume":"73","author":"Izzedine","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0480","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdq550","article-title":"Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients","volume":"22","author":"Vincenzi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0485","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mds577","article-title":"Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG\/AGITG CO.17","volume":"24","author":"Vickers","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0490","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1074\/jbc.M311201200","article-title":"TRPM6\u00a0forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption","volume":"279","author":"Voets","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nephro.2019.06.003_bib0495","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.ajkd.2013.01.008","article-title":"Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor","volume":"61","author":"Sasaki","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.06.003_bib0500","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1078155212459668","article-title":"Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer","volume":"19","author":"Ito","year":"2013","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.nephro.2019.06.003_bib0505","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.ajkd.2016.09.011","article-title":"Panitumumab-induced immune complex glomerulonephritis","volume":"69","author":"Izzedine","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.06.003_bib0510","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10157-008-0066-1","article-title":"Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib","volume":"12","author":"Masutani","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0515","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","article-title":"Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy","volume":"22","author":"Kumasaka","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0520","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","article-title":"Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib","volume":"54","author":"Maruyama","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0525","first-page":"513","article-title":"Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy","volume":"2","author":"Kurita","year":"2009","journal-title":"Nephrol Dial Transplant Plus"},{"key":"10.1016\/j.nephro.2019.06.003_bib0530","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-11-2825","article-title":"A phase II study of lapatinib in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"18","author":"de Souza","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nephro.2019.06.003_bib0535","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11739-012-0794-9","article-title":"Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer","volume":"7","author":"Russo","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0540","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1200\/JCO.2008.20.6847","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0545","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2019.06.003_bib0550","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12282-013-0448-4","article-title":"Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature","volume":"22","author":"Taira","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0555","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000335202","article-title":"Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report and review of the current literature","volume":"6","author":"Gottschalk","year":"2011","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.nephro.2019.06.003_bib0560","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1470-2045(06)71014-2","article-title":"Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy","volume":"8","author":"Bader","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0565","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/01.AOG.0000141570.31218.2b","article-title":"Herceptin (trastuzumab) therapy during pregnancy: association with reversible an-hydramnions","volume":"105","author":"Watson","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0570","unstructured":"Food and Drug Administration (FDA). Zolboraf. Highlights of prescribing information. [Disponible sur\u00a0: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202429s000lbl.pdf]"},{"key":"10.1016\/j.nephro.2019.06.003_bib0575","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.12322","article-title":"Vemurafenib significantly decreases glomerular filtration rate","volume":"28","author":"Uthurriague","year":"2014","journal-title":"J Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0580","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/bjd.12555","article-title":"Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas","volume":"169","author":"Regnier-Rosencher","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0585","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/cncr.28709","article-title":"Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8\u00a0patients","volume":"120","author":"Launay-Vacher","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0590","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated withdabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.nephro.2019.06.003_bib0595","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0600","doi-asserted-by":"crossref","first-page":"e0149873","DOI":"10.1371\/journal.pone.0149873","article-title":"Mechanisms underpinning increased plasma creatinine levels in patients receiving vemurafenib for advanced melanoma","volume":"11","author":"Hurabielle","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2019.06.003_bib0605","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamadermatol.2014.4529","article-title":"Fanconi syndrome induced by vemurafenib: a new renal adverse event","volume":"151","author":"Denis","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0610","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/1346-8138.12430","article-title":"Case of vemurafenibinduced Sweet's syndrome","volume":"41","author":"Yorio","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0615","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"BRAF inhibitor related nephrotoxicity","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0620","unstructured":"Food and Drug Administration (FDA). Tefinlar. Highlights of prescribing information. [Disponible sur\u00a0: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202806s000lbl.pdf]"},{"key":"10.1016\/j.nephro.2019.06.003_bib0625","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600\u00a0mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0630","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non small cell lung cancer: updated results from a phase 1\u00a0study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0635","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.nephro.2019.06.003_bib0640","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lungcan.2014.03.001","article-title":"Crizotinib and renal insufficiency: a case report and review of the literature","volume":"84","author":"Mart\u00edn Martorell","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0645","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","article-title":"Acute kidney injury following crizotinib administration for non small cell lung carcinoma","volume":"82","author":"Gastaud","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0650","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.28478","article-title":"Drug induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib","volume":"120","author":"Brosnan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0655","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1097\/JTO.0000000000000326","article-title":"Development of renal cysts after crizotinib treatment in advanced ALK-positive non small cell lung cancer","volume":"9","author":"Lin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0660","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1634\/theoncologist.2014-0216","article-title":"Spontaneous regression of crizotinib associated complex renal cysts during continuous crizotinib treatment","volume":"19","author":"Klempner","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.nephro.2019.06.003_bib0665","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cam4.437","article-title":"Complex renal cysts associated with crizotinib treatment","volume":"4","author":"Schnell","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0670","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1\u00a0pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.nephro.2019.06.003_bib0675","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18\u00a0induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.nephro.2019.06.003_bib0680","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11912-012-0284-2","article-title":"Programmed death 1\u00a0pathway inhibition in metastatic renal cell cancer and prostate cancer","volume":"15","author":"Tang","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.nephro.2019.06.003_bib0685","article-title":"Toxicit\u00e9s r\u00e9nales des inhibiteurs des points de contr\u00f4le de l\u2019auto-immunit\u00e9","author":"Izzedine","year":"2019","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2019.06.003_bib0690","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death (PD)-1\u00a0inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.06.003_bib0695","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.06.003_bib0700","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-014-0092-7","article-title":"Kidney injuries related to ipilimumab","volume":"32","author":"Izzedine","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.nephro.2019.06.003_bib0705","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1097\/MJT.0b013e3182a32ddc","article-title":"Ipilimumab granulomatous interstitial nephritis","volume":"22","author":"Thajudeen","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.nephro.2019.06.003_bib0710","first-page":"4607","article-title":"Ipilimumab induced immune-related renal failure \u2013 a case report","volume":"32","author":"Forde","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nephro.2019.06.003_bib0715","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti CTLA-4\u00a0antibody induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0720","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","article-title":"Ipilimumab associated minimal change disease","volume":"89","author":"Kidd","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2019.06.003_bib0725","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12032-010-9794-7","article-title":"Hyponatremia associated with ipilimumab-induced hypophysitis","volume":"29","author":"Barnard","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0730","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","article-title":"Nivolumab-associated acute glomerulonephritis: a case report and literature review","volume":"17","author":"Jung","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0735","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor-associated glomerulonephritis","volume":"4","author":"Ashour","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nephro.2019.06.003_bib0740","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nephro.2019.06.003_bib0745","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2\u00a0cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.06.003_bib0750","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","article-title":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma","volume":"16","author":"Bickel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12882-018-0958-6","article-title":"Minimal change disease associated with anti-PD1\u00a0immunotherapy: a case report","volume":"19","author":"Gao","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0760","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.nephro.2019.06.003_bib0765","first-page":"102A","article-title":"Membranous nephropathy related to the checkpoint inhibitor nivolumab","volume":"27","author":"Jonathan","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0770","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nephro.2019.06.003_bib0775","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"A case of IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0780","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.nephro.2019.06.003_bib0785","first-page":"A247","article-title":"Granulomatosis with polyangitis assosciated with immune checkpoint blockade: case report and literature review","volume":"950","author":"Ina Cusnir","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0790","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1\u00a0inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2019.06.003_bib0795","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1\u00a0treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nephro.2019.06.003_bib0800","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4\u00a0antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.nephro.2019.06.003_bib0805","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0810","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0815","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2019.06.003_bib0820","first-page":"3465","article-title":"Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab","volume":"27","author":"Pande","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.nephro.2019.06.003_bib0825","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/annonc\/mdq743","article-title":"Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?","volume":"22","author":"Izzedine","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nephro.2019.06.003_bib0830","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signaling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"10.1016\/j.nephro.2019.06.003_bib0835","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce \u201cpre-eclampsia-like syndrome\u201d: a RARe study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2019.06.003_bib0840","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.nephro.2019.06.003_bib0845","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2019.06.003_bib1430","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519305310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725519305310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2019.06.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:26:43Z","timestamp":1741188403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725519305310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1769725519305310"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2019.06.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicit\u00e9s r\u00e9nales des th\u00e9rapies cibl\u00e9es en oncologie","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation.","name":"copyright","label":"Copyright"}]}}